Silence Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

silence-therapeutics.com

Silence Therapeutics has not claimed their Profile.

Want to better differentiate Silence Therapeutics between your competitors? Show buyers how.

Ionis Pharmaceuticals company logo

Why does Silence Therapeutics win vs. Ionis Pharmaceuticals?

Show Silence Therapeutics's primary competitive advantage
Show Silence Therapeutics's competitive differentiation

Silence Therapeutics's alternatives and competitors

See how Silence Therapeutics compares to similar products. Silence Therapeutics's top competitors include Ionis Pharmaceuticals.

Ionis Pharmaceuticals discovers and develops RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy (SMA) in pediatric a…

Silence Therapeutics vs. Ionis Pharmaceuticals

View more in-depth data on:

  • Competitors
  • Products
  • Customer References and more

    Top Silence Therapeutics competitor

    Work for Silence Therapeutics?

    Brief our analysts.

    Get in front of tech buyers.

    100% free.

    No pay-to-play nonsense.

    You May Also Like

    Dicerna Pharmaceuticals Logo
    Dicerna Pharmaceuticals

    Dicerna Pharmaceuticals is a pharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, including cancer. Dicerna's therapeutic approach utilizes its Dicer Substrate siRNA (DsiRNA) molecules and EnCore drug delivery technologies to silence previously undruggable disease targets, offering a potential new treatment option for patients. Dicerna delivers its DsiRNA molecules to cancer cells using its EnCore lipid nanoparticle drug delivery technology. EnCore has been specifically engineered to accumulate in tumors and mediate efficient delivery of the DsiRNAs to the RNAi machinery in the cancer cell cytoplasm. Encore particles are well tolerated and manufactured using well-established unit operations to ensure commercial scalability.

    A
    Arrowhead Pharmaceuticals

    Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

    Akcea Therapeutics Logo
    Akcea Therapeutics

    Akcea Therapeutics (NASDAQ: AKCA) is a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.

    Regulus Therapeutics Logo
    Regulus Therapeutics

    Regulus Therapeutics (NASDAQ: RGLS), a biopharmaceutical company, focuses on the discovery and development of drugs that target RNAs to treat a range of diseases in the United States. The Company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 to treat nonalcoholic steatohepatitis in patients with type 2 diabetes/pre-diabetes. The company has strategic alliance with GSK to discover and develop microRNA therapeutics for immuno-inflammatory diseases; Sanofi to discover and develop microRNA therapeutics for fibrotic diseases; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and Biogen to evaluate the use of microRNA signatures as a biomarker for human patients with various sclerosis.

    Sarepta Therapeutics Logo
    Sarepta Therapeutics

    Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates.

    Alnylam Pharmaceuticals Logo
    Alnylam Pharmaceuticals

    Alnylam Pharmaceuticals (NASDAQ: ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company believes that are many new therapeutic frontiers for its RNA technology, including applications in vaccine development, stem cell biology, bio-processing, genomics and biologics.

    Discover the right solution for your team

    The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

    Request a demo

    CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.